nVerses Capital’s Starling Oncology STLN Stock Holding History

nVerses Capital’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31,595	Closed	-$112K	–	474
2025 Q4	$112K	Buy	+31,595	New	+$117K	0.25%	161

Other funds holding STLN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $413M AUM 109.83% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

nVerses Capital's STLN Position: Q1 2026 in Review

nVerses Capital sold out of Starling Oncology (STLN) in Q1 2026, closing a stake of 31,595 shares — an estimated $112K sold.

nVerses Capital first reported a position in STLN in Q4 2025 and held it in 1 quarter. The position peaked at $112K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

nVerses Capital reported no remaining Starling Oncology position as of Q1 2026 after selling out during the quarter.
nVerses Capital sold 31,595 Starling Oncology shares in Q1 2026, an estimated $112K.
nVerses Capital first reported a position in Starling Oncology in Q4 2025 and held it in 1 quarter.
nVerses Capital's Starling Oncology position peaked at $112K in Q4 2025.
115 funds tracked by Wall St. Rank held Starling Oncology as of Q1 2026.

Based on nVerses Capital's 13F filing for Q1 2026, filed 13 May 2026.